1. Southgate K, Creagh F, Teece M, Kingswood C, Rees Smith B. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol. 1984. 20:539–548.

2. Rees Smith B, Rickards CR, Davies Jones E, Kajita Y, Buckland PR, Creagh FM, Howells RD, Hashim F, Parkes AB, Petersen VB. The thyrotropin receptor and its role in Graves' disease. J Endocrinol Invest. 1985. 8:175–182.

3. Gupta MK. Thyrotropin receptor antibodies: advances and importance of detection techniques in thyroid diseases. Clin Biochem. 1992. 25:193–199.

4. Massart C, Hody B, Mouchel L, Edan G, Nicol M. Assays for thyrotropin-receptor binding and thyroid-stimulating antibodies in sera from patients with Graves' disease. Clin Chemistry. 1986. 32:1332–1335.

5. Weetman A, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocrine Review. 1994. 15:788–830.

6. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G, Usadel KH. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab. 1999. 84:90–97.

7. Frazier AL, Robbins LS, Stork PJ, Sprengel R, Segaloff DL, Cone RD. Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation by tissue specific splicing. Mol Endocrinol. 1990. 4:1264–1276.

8. Sanders J, Oda Y, Roberts S, Kiddie A, Richards T, Bolton J, McGrath V, Walters S, Jaskolski D, Furmaniak J, Smith BR. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor. J Clin Endocrinol Metab. 1999. 84:3797–3802.

9. Bolton J, Sanders J, Oda Y, Chapman C, Konno R, Furmaniak J, Rees Smith B. Measurement of thyroid -stimulating hormone receptor autoantibodies by ELISA. Clin Chem. 1999. 45:2285–2287.

10. Rees Smith B, Sander J, Furmaniak J. TSH receptor antibodies. Thyroid. 2007. 17:923–938.

11. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G, Usadel KH. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab. 1999. 84:90–97.

12. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrino. 2001. 55:381 –390.

13. Kakinuma A, Morimoto I, Kuroda T, Fujihira T, Eto S, McLachlan SM, Rapoport B. Comparison of recombinant human thyrotropin receptors versus porcine thyrotropin receptors in the thyrotropin binding inhibition assay for thyrotropin receptor autoantibodies. Thyroid. 1999. 9:849–855.

14. Rees Smith B. Thyroid autoantibodies. Scand J Clin Lab Invest. 2001. 61:Suppl 235. 45–52.

15. Paunkovic J, Paunkovic N. Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis. Horm Metab Res. 2006. 38:53–56.

16. Giovanella L, Ceriani L, Garancini S. Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st generation test. Clin Chem Lab Med. 2001. 39:25–28.

17. Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J, Furmaniak J. A new assay for thyrotropin receptor autoantibodies. Thyroid. 2004. 14:830–835.

18. Huh JE, Suk JH, Kim MK, Choi IJ, Son SM, Kim IJ, Kim YK. Clinical Usefulness of the Second Generation TSH-Binding Inhibitory Immunoglobulin Assay Using Recombinant Human TSH Receptor in Patients with Graves' Disease. J Korean Endocr Soc. 2008. 23:179–185.

19. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol. 2008. [Epub ahead of print].

20. Okamoto Y, Tanigawa S, Ishikawa K, Hamada N. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J. 2006. 53:467–472.

21. Massart C, Orgiazzi J, Maugendre D. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta. 2001. 304:39–47.

22. Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol. 2001. 54:89–96.

23. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE; Basedow Study Group. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid. 2005. 15:1047–1054.

24. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol. 2002. 146:173–177.

25. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res. 2004. 36:92–96.

26. Sanders J, Evans M, Premawardhana LD, Depraetere H, Jeffreys J, Richards T, Furmaniak J, Rees Smith B. Human monoclonal thyroid stimulating autoantibody. Lancet. 2003. 362:126–128.

27. Kamijo K, Ishikawa K, Tanaka M. Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J. 2005. 52:525–529.